The immunological fitness of NSCLC patients drives the response to anti-PD1-based immunotherapy regardless of age

Abstract Background Over the past decade, the number of elderly cancer patients has increased, including those with NSCLCs, most of whom are over 60 years old. NSCLC patients receive anti-PD1-based therapies. These therapies directly target the immune system by activating T cells. However, older pat...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Lucrezia Tuosto, Alain Gelibter, Lidia Strigari, Angela Asquino, Marco Siringo, Angelica Pace, Flavio Valentino, Davide Capozzi, Serena Bianchini, Filippo Bellati, Daniele Santini, Marianna Nuti, Ilaria Grazia Zizzari, Aurelia Rughetti, Chiara Napoletano
Format:	Artigo
Sprog:	Inglês
Udgivet:	BMC 2026-02-01
Serier:	Journal of Translational Medicine
Fag:	Non-small cell lung cancer Elderly patients anti-PD1 treatment Immunotherapy
Online adgang:	https://doi.org/10.1186/s12967-026-07719-9
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!